Durable viral suppression in the dolutegravir era: a data-enabled, risk-stratified model for integrated HIV care in Uganda.

TL;DR

Despite near-universal access to potent dolutegravir-based HIV therapy in Uganda, 6.4% of patients still have detectable viral loads, with regional data suggesting 19.4% viral non-suppression. The study identifies that viral control depends less on drug efficacy and more on identifying high-risk patients early and delivering integrated care for TB and non-communicable diseases.

What the Study Found

Uganda's experience with dolutegravir rollout reveals a crucial gap between pharmacology and real-world outcomes. The AIDS Support Organization (TASO) analyzed 54,348 people living with HIV between 2014 and 2024, tracking outcomes as integrase inhibitor adoption became nearly universal across the country. Among patients with recorded viral load data, only 6.4% had detectable viremia (viral load ≥1,000 copies/mL). On the surface, this suggests success. But the researchers asked a more important question: why is viral suppression incomplete when the drug itself is highly potent?

The answer points to implementation gaps rather than regimen failure. A parallel systematic review of 29,829 patients across the East African region found that viral non-suppression concentrates predictably within specific social and clinical risk groups. The 19.4% regional estimate contrasts sharply with TASO's 6.4% figure, suggesting that organizational capacity and care models significantly influence outcomes. The study identified tuberculosis co-infection and non-communicable diseases (NCDs) like hypertension and diabetes as common comorbidities that frequently went undetected or unmanaged within routine HIV programs.

The researchers propose that durable suppression requires three interconnected mechanisms: first, a time-bound viral load cascade with defined intervals between testing, treatment initiation, and follow-up confirmation; second, rapid identification of patients at elevated risk through electronic health record (EHR) systems; and third, targeted delivery of "adherence and socioeconomic stability bundles" that address barriers beyond drug availability. Examples include food insecurity assistance, transportation support, and simplified pill regimens. Critically, the model integrates TB screening and NCD management into HIV care platforms rather than treating them as separate systems. Advanced HIV disease (AHD), defined by very low CD4 counts at presentation, remained common despite drug availability, suggesting many patients entered care late or lost contact with services.

The authors emphasize that a simple dashboard tracking cascade timeliness, high-risk package delivery uptake, and integrated care coverage could translate existing ART scale-up investments into measurable progress toward the UNAIDS 95-95-95 targets (95% diagnosed, 95% treated, 95% virally suppressed). The model is pragmatic: it builds on existing WHO guidance for differentiated service delivery and AHD management, requires no new drugs, and leverages routine data systems already in place.

What This Means for You

This research speaks primarily to healthcare systems and policymakers, but the underlying insight is relevant to anyone managing HIV or chronic conditions.

For people living with HIV: The study underscores that viral control depends on more than taking a good drug. Predictable barriers like food insecurity, transportation, stigma, and competing health priorities affect adherence. If you're struggling to take medications consistently, flagging this to your clinician early allows rapid intervention rather than waiting for a missed viral load test to reveal the problem. Similarly, if you have TB symptoms or conditions like diabetes, integrating their management into your HIV care visit reduces the need for multiple clinic trips.

For care providers and systems: Passive monitoring is insufficient. EHR systems that flag patients at risk of falling out of care, combined with proactive follow-up protocols, outperform reactive approaches. Investing in data infrastructure and staffing for rapid viral non-suppression response yields measurable gains. The research suggests that high-performing sites (like TASO, which achieved 6.4% viral non-suppression) systematically identify barriers and address them through targeted support, not generic adherence counseling.

For health policy: The case for integrated care is no longer aspirational. TB and NCD screening should occur automatically during HIV visits; managing them separately perpetuates preventable morbidity and mortality. Differentiated service delivery models that reduce clinic frequency for stable patients free capacity to intensively support unstable patients.

Study Details

Sources

Ugandan research team. "Durable viral suppression in the dolutegravir era: a data-enabled, risk-stratified model for integrated HIV care in Uganda." *Frontiers in Public Health*. PubMed: 42158193